As the modulation of HSP90 results in changes in multiple pathways, further studies are necessary to define in detail how HSP90 inhibitors exert their beneficial effect in IPF, the optimal dose strategy, and potential side effects. This evidence concerns the gene HSP90AA1 and idiopathic pulmonary fibrosis.